As of March 31, 2025, Spyre had cash, cash equivalents, and marketable securities of $564.8M. “We continued to efficiently execute on our ambitious strategy this quarter – presenting longer-term SPY001 Phase 1 data that further supports its potential best-in-class profile, continuing dosing with our SPY002 molecules in parallel Phase 1 trials, and initiating our fourth Phase 1 trial within nine months with SPY003,” said CEO Cameron Turtle. “This quarter, we look forward to sharing interim SPY002 Phase 1 data which has the potential to demonstrate a best-in-class profile for the treatment of IBD and other immune-mediated diseases, as well as a second optimized component of our potentially paradigm-changing investigational combination therapies. Following these data, we plan to embark on two fully funded, groundbreaking Phase 2 trials that will provide 7+ proof-of-concept readouts in markets with annual revenues totaling approximately $50B. With de-risked biology, an experienced team, and a strong balance sheet, we are focused on delivering against our plans to redefine the standard-of-care in IBD and beyond while providing a transformative set of catalysts for our investors.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- SYRE Upcoming Earnings Report: What to Expect?
- Spyre Therapeutics’ SPY001 shows efficacy in two poster presentations
- Leerink bullish on Spyre Therapeutics, initiates with an Outperform
- Spyre Therapeutics initiated with an Outperform at Leerink
- Promising Outlook for Spyre Therapeutics’ SPY003: Potential Game-Changer in IBD Treatment